Pauline Funchain, Medical Oncologist/Cancer Genomics at Cleveland Clinic, shared on X:
”Great advances in sarcoma Nam Bui, Stanford Cancer Institute reviews ASCO26 highlights ANCO
- bezuclastinib+sunitinib new 2L SOC for sarcoma
- ozekibart heading to first FDA approval for chondrosarcoma
- significant ORR improvement (55 v 9%) with varegacestat for desmoid tumor.”
Other articles about ASCO26 on OncoDaily.